Contributions
Abstract: P853
Type: Poster
Abstract Category: Clinical aspects of MS - 2 MS Variants
Background: Cortical demyelination and gray matter atrophy are more prominent to occur in primary progressive multiple sclerosis (PPMS) than in relapsing-remitting multiple sclerosis (RRMS) patients.
Objectives: To identify changes in cortical grey matter thickness (CGMT) measurements related to whole-brain, deep, and cortical gray matter in PPMS patients as compared with RRMS patients.
Design and methods: Cross sectional study comparing cortical grey matter thickness (CGMT) between PPMS and RRMS patients pair-matched for age, gender and disease duration. All patients underwent 3 dimensional fast spoiled gradient recalled (3D FSPGR) brain MRI scans. Freesurfer 5.3 software was used to obtain whole brain volumetric segmentation of subcortical regions and corresponding cortical thickness measurements. Paired t-test was performed to assess group differences using SPSS 24.0.
Results: Ninety two MS patients were evaluated, 46 PPMS patients and 46 RRMS patients (25/21 F/M), mean±SD age 50.2±10.9yr, range 22-67yr, disease duration 10.7±7.7yr, EDSS in the PPMS group 4.5±1.6, 91.3% of patients had motor functional score ≥2, and EDSS in the RRMS group 3.2±1.9,63% of patients had motor functional score ≥2, p=0.001. Surface based analysis demonstrated a decrease in CGMT in the PPMS group in the post-central area in the right hemisphere (-10.4%, p=0.02) and in the inferior-temporal area in the left hemisphere (-10%, p=0.01). Subcortical structures analysis showed no significant differences between the RRMS and the PPMS groups.
Conclusion: CGMT is more impaired in PPMS patients as compared to RRMS patients, mainly involving areas related to motor function and visual discrimination.
Disclosure:
Pardo K: nothing to disclose
Or Bach L: nothing to disclose
Menascu S: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).Dolev M: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Magalashvili D: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Achiron A: Consulting fees: (EMD Serono, Genzyme, Roche); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Abstract: P853
Type: Poster
Abstract Category: Clinical aspects of MS - 2 MS Variants
Background: Cortical demyelination and gray matter atrophy are more prominent to occur in primary progressive multiple sclerosis (PPMS) than in relapsing-remitting multiple sclerosis (RRMS) patients.
Objectives: To identify changes in cortical grey matter thickness (CGMT) measurements related to whole-brain, deep, and cortical gray matter in PPMS patients as compared with RRMS patients.
Design and methods: Cross sectional study comparing cortical grey matter thickness (CGMT) between PPMS and RRMS patients pair-matched for age, gender and disease duration. All patients underwent 3 dimensional fast spoiled gradient recalled (3D FSPGR) brain MRI scans. Freesurfer 5.3 software was used to obtain whole brain volumetric segmentation of subcortical regions and corresponding cortical thickness measurements. Paired t-test was performed to assess group differences using SPSS 24.0.
Results: Ninety two MS patients were evaluated, 46 PPMS patients and 46 RRMS patients (25/21 F/M), mean±SD age 50.2±10.9yr, range 22-67yr, disease duration 10.7±7.7yr, EDSS in the PPMS group 4.5±1.6, 91.3% of patients had motor functional score ≥2, and EDSS in the RRMS group 3.2±1.9,63% of patients had motor functional score ≥2, p=0.001. Surface based analysis demonstrated a decrease in CGMT in the PPMS group in the post-central area in the right hemisphere (-10.4%, p=0.02) and in the inferior-temporal area in the left hemisphere (-10%, p=0.01). Subcortical structures analysis showed no significant differences between the RRMS and the PPMS groups.
Conclusion: CGMT is more impaired in PPMS patients as compared to RRMS patients, mainly involving areas related to motor function and visual discrimination.
Disclosure:
Pardo K: nothing to disclose
Or Bach L: nothing to disclose
Menascu S: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).Dolev M: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Magalashvili D: Consulting fees: (Genzyme); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).
Achiron A: Consulting fees: (EMD Serono, Genzyme, Roche); contracted research (Bayer, Biogen Idec, EMD Serono, Genzyme, Roche).